Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

100.63
Delayed Data
As of 4:14pm ET
 -2.25 / -2.19%
Today’s Change
55.00
Today|||52-Week Range
118.49
-7.21%
Year-to-Date
Gilead Sciences Inc.'s Worst Moves in 2016
Dec 06 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy in December
Dec 01 / MotleyFool.com - Paid Partner Content
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
Dec 05 / Zacks.com - Paid Partner Content
3 Biotech Stocks to Buy on Sale
Nov 29 / MotleyFool.com - Paid Partner Content
3 Reasons Why Incyte Corporation Stock Could Soar in 2017
Dec 03 / MotleyFool.com - Paid Partner Content
Intellipharmaceutics Submits NDA for Pain Treatment Rexista
Nov 28 / Zacks.com - Paid Partner Content
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
Dec 01 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close102.88
Today’s open103.85
Day’s range100.02 - 105.48
Volume1,078,620
Average volume (3 months)1,404,273
Market cap$19.4B
Dividend yield--
Data as of 4:14pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+1,860.50%
Earnings growth (next 5 years)+170.10%
Revenue growth (last year)+47.36%
P/E ratio127.4
Price/Sales26.95
Price/Book112.19

Competitors

 Today’s
change
Today’s
% change
MYLMylan NV+0.45+1.25%
VRTXVertex Pharmaceutica...-0.55-0.71%
BAXBaxter International...+0.76+1.72%
BMRNBiomarin Pharmaceuti...-0.83-0.99%
Data as of 4:01pm ET, 12/09/2016

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)$0.13
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts


Search for Jobs